Evidence map›Paper›PMID 36894954›Full record

ArticleParasites & vectors2023

Insecticidal activity of Simparica and Simparica Trio against Aedes aegypti in dogs.

Thomas Geurden, Sara Chapin, John W McCall, Abdelmoneim Mansour, Sean P Mahabir, Kristina Kryda, Tom McTier

Open access · goldAbstract readRandomized Controlled Trial, Veterinary
In one paragraph

Article in Parasites & vectors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Safeguarding Canadian pets and humans: A call to strengthen regulations for importing companion animals.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2026
    Review
  3. Article
  4. Review
  5. Fluralaner (BravectoParasites & vectors · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Thomas GeurdenZoetis Incorporated, Mercuriusstraat 20, 1390, Zaventem, Belgium. Thomas.geurden@zoetis.com.
Sara ChapinZoetis Incorporated, Kalamazoo, MI, 49007, USA.
John W McCallTRS Labs, Incorporated, Athens, GA, 30607, USA.
Abdelmoneim MansourTRS Labs, Incorporated, Athens, GA, 30607, USA.
Sean P MahabirZoetis Incorporated, Kalamazoo, MI, 49007, USA.
Kristina KrydaZoetis Incorporated, Kalamazoo, MI, 49007, USA.
Tom McTierZoetis Incorporated, Kalamazoo, MI, 49007, USA.
Zoetis (United States) · USTRS Technologies (United States) · USZoetis (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAedes aegypti is one of the main species responsible for the transmission of mosquito-borne pathogens worldwide. The isoxazoline Sarolaner has excellent efficacy as an acaricide against ticks and mites and as an insecticide against fleas, and potential efficacy against other insects.

methodsIn each of two laboratory studies, 24 dogs were randomly allocated (n = 8/group) to an untreated control group, a Simparica-treated group (at the minimum dose of 2.0 mg/kg sarolaner), or a Simparica Trio-treated group (at the minimum dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel), based on pre-treatment mosquito counts. Treatments were administered orally once on day 0. Each dog was exposed to 50 unfed female adult A. aegypti mosquitoes for 1 h on days 1, 7, 14, 21, 28 and 35. After each exposure, mosquitoes were counted for each dog and characterized as live, moribund or dead, and as fed or unfed. Dead mosquitoes were counted and removed at 12, 24 and 48 h post-exposure in study 1 and at 24, 48, 72, 96 and 120 h post-exposure in study 2. In study 2, mosquito eggs were collected from 72 h post-exposure until 120 h post-exposure. Insecticidal efficacy was calculated based on the reduction of the arithmetic mean live fed-mosquito counts in each of the treated groups versus the untreated control group for every timepoint post-exposure.

resultsAdequate challenge was demonstrated in both studies, with arithmetic mean live fed-mosquito counts ranging from 35.5 to 45.0 for the untreated group. Mean mosquito counts for dogs treated with Simparica and Simparica Trio were significantly (P < 0.0001) reduced within 48 h after exposure on all study days. In study 1, Simparica treatment provided ≥ 96.8% reduction in the arithmetic mean live fed-mosquito counts for 28 days, and Simparica Trio treatment provided ≥ 90.3% reduction for 21 days. In study 2, Simparica treatment provided ≥ 99.4% reduction for 35 days (from 48 h onwards), and Simparica Trio treatment provided ≥ 97.8% reduction for 28 days (from 72 h onwards).

conclusionsBoth studies demonstrated that a single oral dose of Simparica or Simparica Trio provides high efficacy against mosquitoes in dogs within 24-72 h after exposure for an entire month.

Indexed as

AedesDog DiseasesInsecticidesTick InfestationsAdministration, OralAnimalsAzetidinesDogsDrug CombinationsFemaleMacrolidesParasite LoadPyrantelSpiro CompoundsTreatment OutcomeAzetidinesDrug CombinationsInsecticidesMacrolidesmoxidectinPyrantelsarolanerSpiro CompoundsAedes aegyptiDogsEfficacyInsecticidalIsoxazolineMosquitoSarolaner

Identifiers

PMID36894954
PMCPMC9999496
OpenAlexW4323812758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.